Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $2.9 million.

  • Iradimed's Change in Receivables rose 26991.16% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year increase of 23908.58%. This contributed to the annual value of -$1.8 million for FY2024, which is 10929.47% down from last year.
  • As of Q3 2025, Iradimed's Change in Receivables stood at $2.9 million, which was up 26991.16% from -$1.8 million recorded in Q2 2025.
  • Iradimed's 5-year Change in Receivables high stood at $2.9 million for Q3 2025, and its period low was -$1.8 million during Q2 2025.
  • For the 5-year period, Iradimed's Change in Receivables averaged around $496351.5, with its median value being $369255.0 (2021).
  • As far as peak fluctuations go, Iradimed's Change in Receivables surged by 1538654.78% in 2022, and later crashed by 21302.53% in 2023.
  • Quarter analysis of 5 years shows Iradimed's Change in Receivables stood at $897395.0 in 2021, then skyrocketed by 197.52% to $2.7 million in 2022, then plummeted by 118.68% to -$498857.0 in 2023, then soared by 137.85% to $188810.0 in 2024, then skyrocketed by 1428.48% to $2.9 million in 2025.
  • Its Change in Receivables stands at $2.9 million for Q3 2025, versus -$1.8 million for Q2 2025 and $2.1 million for Q1 2025.